Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
The FDA recommended that Compass run a survival-benefit trial before seeking approval for tovecimig in previously treated, advanced biliary tract cancer. That feedback shifts the program toward a larger clinical and regulatory hurdle before a BLA can proceed.
Compass Therapeutics said Sept. 22 that the FDA recommended a trial demonstrating a survival benefit for tovecimig in patients with previously treated, advanced biliary tract cancer. The recommendation came after FDA feedback and concerns the path to a Biologics License Application.
Compass is developing tovecimig for biliary tract cancer, a setting in which the company had been considering a BLA submission. The regulatory feedback changes that sequence by placing a survival-benefit trial ahead of the filing.
The decision directly affects Compass Therapeutics and its tovecimig program. The concrete mechanism is regulatory: a new trial would be required before the company could proceed with a BLA submission for this indication.
The announcement describes the FDA's recommendation rather than an approval decision, and the timing, design and outcome of any additional trial remain open. The next markers are Compass's plans for the study, any further FDA interactions and whether the company identifies a timetable for a potential BLA.
FDA recommended that Compass Therapeutics (CMPX) run a survival-benefit trial before filing tovecimig’s biliary cancer application.
The added trial requirement lengthens the path to a BLA and introduces another efficacy hurdle before the program can advance toward approval. No dated next event is established, so the regulatory consequence is clear but does not support a forward directional call.
Compass could narrow or resolve the regulatory requirements through follow-up discussions with the FDA, or a future survival-benefit study could support the application.
CoverageSource: GlobeNewswire · Published here TUE, SEP 22 · 8:30 AM ET · the only report in this recordHow this is decided →
Earlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
The program remains active, and a successful survival-benefit trial could preserve a future BLA path in previously treated, advanced biliary tract cancer.
The FDA recommendation adds a required clinical hurdle before filing, leaving the timing and outcome of the approval path uncertain.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →